Teva Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Reports In-Line Q4 EPS, Offers Guidance
February 8, 2023 7:09 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.88 billion.
GUIDANCE:
Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of... More
